eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on Ph 2 Trial of Zotatifin Combo in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer May 21, 2024
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics May 21, 2024
AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore May 21, 2024
First Patient Dosed in Investigator-Initiated Trial (IIT) of Danvatirsen in Ph 1 for AML/MDS Cancers May 21, 2024
RAPHAEL Registrational Ph 3 Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated R/R AML in China Initiated May 21, 2024
Ph 2/3 Trial of Surufatinib + Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui Initiated May 21, 2024
FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer May 21, 2024
First Patient Dosed in Ph 1 Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML May 21, 2024
WITHDRAWN: FDA withdraws accelerated approval to infigratinib for metastatic cholangiocarcinoma May 21, 2024
Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck To Study Combination of Bavencio® With AU-007 May 21, 2024
Updated Clinical Data from Ph 1b Trial of Vepdegestrant + Palbociclib (IBRANCE) Announced May 21, 2024
US FDA accepts Protocol for New Randomized Ph 2 Study of NBTXR3 for Patients with Stage 3 Lung Cancer May 21, 2024
FDA approves Imdelltra™ (tarlatamab-dlle) for The Treatment Of Extensive-Stage Small Cell Lung Cancer May 21, 2024
China CDE Clearance for Ph 3 Trial of KRAS G12C Inhibitor Glecirasib in Patients with CRC Announced May 21, 2024
Paediatric Investigation Plan Waiver Received from the European Medicines Agency for Certepetide in Pancreatic Cancer May 21, 2024
